Cormorant Asset Management’s Regulus Therapeutics RGLS Stock Holding History

Cormorant Asset Management’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-255	Closed	-$212K	–	87
2016 Q1	$212K	Hold	255	–	–	0.03%	81
2015 Q4	$267K	Sell	255 -7,216	-97%	-$7.23M	0.03%	82
2015 Q3	$5.86M	Hold	7,471	–	–	0.94%	34
2015 Q2	$9.83M	Hold	7,471	–	–	1.31%	26
2015 Q1	$15.2M	Sell	7,471 -1,696	-19%	-$3.69M	2.35%	13
2014 Q4	$17.6M	Buy	9,167 +7,500	+450%	+$13.3M	2.72%	10
2014 Q3	$1.37M	Hold	1,667	–	–	0.28%	55
2014 Q2	$1.61M	Hold	1,667	–	–	0.43%	49
2014 Q1	$1.8M	Buy	1,667 +834	+100%	+$924K	0.41%	44
2013 Q4	$739K	Buy	+833	New	+$717K	0.21%	32

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

SDIC

South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cormorant Asset Management's RGLS Position: Q2 2016 in Review

Cormorant Asset Management sold out of Regulus Therapeutics (RGLS) in Q2 2016, closing a stake of 255 shares — an estimated $212K sold.

Cormorant Asset Management first reported a position in RGLS in Q4 2013 and held it in 10 quarters. The position peaked at $17.6M in Q4 2014. 83 funds tracked by Wall St. Rank hold RGLS as of Q2 2016.

Cormorant Asset Management reported no remaining Regulus Therapeutics position as of Q2 2016 after selling out during the quarter.
Cormorant Asset Management sold 255 Regulus Therapeutics shares in Q2 2016, an estimated $212K.
Cormorant Asset Management first reported a position in Regulus Therapeutics in Q4 2013 and held it in 10 quarters.
Cormorant Asset Management's Regulus Therapeutics position peaked at $17.6M in Q4 2014.
83 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2016.

Based on Cormorant Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.